Leerink Partners Resumes Invitae Corporation (NVTA) at Outperform

November 10, 2016 8:41 AM EST
Get Alerts NVTA Hot Sheet
Price: $7.05 +1.44%

Rating Summary:
    3 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade NVTA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink Partners resumes coverage on Invitae Corporation (NYSE: NVTA) with a Outperform rating and a price target of $12.00.

Analyst Puneet Souda commented, "NVTA is a high growth, commercial-stage diagnostics company focused on building a business around genetic testing in a sizable and growing multibillion dollar market. The company has over 1,000 genes currently in production in a variety of flexible panel formats, with a competitive turnaround time and an attractive set pricing. With recent and rapid progress on the reimbursement front, NVTA now has 160M lives covered under commercial payers beyond the positive pricing already announced by CMS. Cancer testing still constitutes 75%-80% of volume for NVTA, and thus reimbursement remains a key despite Medicare being only 8%-10% of the company’s volume."

For an analyst ratings summary and ratings history on Invitae Corporation click here. For more ratings news on Invitae Corporation click here.

Shares of Invitae Corporation closed at $8.44 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Add Your Comment